Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
ConclusionsOur model projected nivolumab+ipilimumab to be cost effective for the non-epithelioid subtype but not for all histologies. Substantial discounts for nivolumab+ipilimumab would be necessary to achieve cost effectiveness for all histologies.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Alimta | Asbestosis | Avastin | Cancer & Oncology | Chemotherapy | Health Insurance | Health Management | Immunotherapy | Insurance | Mesothelioma | Palliative | Study | Switzerland Health | Yervoy